The investors have agreed to purchase the shares of common stock at a price of $6.57 per share, resulting in buy valium online proceeds to Achillion of approximately $41.8 million. The sale was expected to close on generic valium about September 4, subject to closing conditions.
The securities described above are being offered directly to the purchasers by Achillion pursuant to a registration statement previously filed with and subsequently declared effective by the Securities & Exchange Commission.
Achillion is a pharmaceutical developer focused on new treatments for patients with infectious disease, including HCV and resistant bacterial infections.
|< Prev||Next >|